Genis
Pioneering the development of therapeutic chitin derivatives.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $17.0m | Early VC | |
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 427 % | (9 %) | (54 %) | (30 %) | (15 %) | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (280 %) | (56 %) | (50 %) | (83 %) | (144 %) | (280 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (439 %) | (144 %) | (157 %) | (392 %) | (672 %) | (1020 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
Genis.is operates in the health and wellness sector, focusing on the development and sale of innovative health supplements. The company primarily serves health-conscious consumers looking to improve cognitive function and sleep quality. Genis.is leverages scientific research to formulate its products, ensuring efficacy and safety for its users. The business model is direct-to-consumer, with products available for purchase through their online platform. Revenue is generated through the sale of these health supplements, which are marketed based on their scientifically-backed benefits. The company operates in multiple European markets, including Germany, the United Kingdom, and Iceland, indicating a broad geographical reach and a diverse customer base.
Keywords: health supplements, cognitive function, sleep quality, scientific research, direct-to-consumer, online sales, European markets, wellness, efficacy, safety.